https://www.businesswire.com/news/home/20260503510264/en/Faraday-Future-Founder-and-Co-CEO-YT-Jia-Shares-Weekly-Investor-Update-EAI-Robotics-Sales-Momentum-Continues-Along-with-University-Collaborations-and-Partnership-Development 2026-05-03T23:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-03T23:00:00.000Z Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: EAI Robotics Sales Momentum Continues Along with University Collaborations and Partnership Development FFAI https://mms.businesswire.com/media/20260503510264/en/2793057/21/0503.jpg https://www.businesswire.com/news/home/20260430389531/pl 2026-05-03T21:31:00.000Z weekly 0.5 Business Wire pl PressRelease 2026-05-03T21:31:00.000Z Rimini Street ogłasza wyniki finansowe i operacyjne za I kwartał roku obrotowego 2026 RMNI https://mms.businesswire.com/media/20260430389531/pl/2790113/21/Q1_2026_Earnings_Announcement_PR_businesswire-2400x2400.jpg https://www.businesswire.com/news/home/20260430088321/zh-HK 2026-05-03T21:30:00.000Z weekly 0.5 Business Wire zh-HK PressRelease 2026-05-03T21:30:00.000Z Rimini Street公布2026會計年度第一季財務和經營業績 RMNI https://mms.businesswire.com/media/20260430088321/zh-HK/2790113/21/Q1_2026_Earnings_Announcement_PR_businesswire-2400x2400.jpg https://www.businesswire.com/news/home/20260430405395/de 2026-05-03T21:25:00.000Z weekly 0.5 Business Wire de PressRelease 2026-05-03T21:25:00.000Z Rimini Street gibt die Finanz- und Betriebsergebnisse für das erste Quartal des Geschäftsjahres 2026 bekannt RMNI https://mms.businesswire.com/media/20260430405395/de/2790113/21/Q1_2026_Earnings_Announcement_PR_businesswire-2400x2400.jpg https://www.businesswire.com/news/home/20260430199194/es 2026-05-03T21:25:00.000Z weekly 0.5 Business Wire es PressRelease 2026-05-03T21:25:00.000Z Rimini Street presenta los resultados financieros y operativos del primer trimestre fiscal de 2026 RMNI https://mms.businesswire.com/media/20260430199194/es/2790113/21/Q1_2026_Earnings_Announcement_PR_businesswire-2400x2400.jpg https://www.businesswire.com/news/home/20260503644332/en/Mirum-Pharmaceuticals-to-Host-Investor-Call-to-Share-Topline-Results-from-the-VISTAS-Study-of-Volixibat-in-Patients-with-Primary-Sclerosing-Cholangitis-on-May-4-2026 2026-05-03T21:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-03T21:00:00.000Z Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 MIRM https://mms.businesswire.com/media/20260503644332/en/746217/21/Mirum_Inline_FullColor_RGB.jpg https://www.businesswire.com/news/home/20260503595444/en/UCB-to-Acquire-Candid-Therapeutics-Building-Upon-Its-Existing-Immunology-Pipeline-With-Novel-T-cell-Engagers 2026-05-03T17:10:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-03T17:10:00.000Z UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers https://mms.businesswire.com/media/20260503595444/en/2792969/21/CandidRx-logo-BIP-SMT-180724_final_72.jpg https://www.businesswire.com/news/home/20260503153460/en/Power-Outage-No-Longer-Anticipated-for-the-Village-of-Hughenden-and-Surrounding-Area-AltaLink-Continues-to-Monitor-Wildfire-Conditions 2026-05-03T16:56:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-03T16:56:00.000Z Power Outage No Longer Anticipated for the Village of Hughenden and Surrounding Area; AltaLink Continues to Monitor Wildfire Conditions https://mms.businesswire.com/media/20260503153460/en/2619622/21/altalink.jpg https://www.businesswire.com/news/home/20260503221597/en/A-World-Reshaped-by-Disruption.-A-Conference-Built-to-Respond 2026-05-03T16:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-03T16:00:00.000Z A World Reshaped by Disruption. A Conference Built to Respond https://mms.businesswire.com/media/20260503221597/en/1642423/21/MI_MAIN_Solid_Blue_Horizontal_Logo-RGB.jpg https://www.businesswire.com/news/home/20260501613704/de 2026-05-03T13:50:00.000Z weekly 0.5 Business Wire de PressRelease 2026-05-03T13:50:00.000Z Incyte gibt die FDA-Zulassung von Jakafi XR™ (Ruxolitinib) Retardtabletten zur Behandlung von Myelofibrose, Polycythaemia vera und Graft-versus-Host-Erkrankung bekannt INCY https://mms.businesswire.com/media/20260501613704/de/2792366/21/JAKAFIXR_US_TM_5dose_RGB_FC_Pos_White-002.jpg https://www.businesswire.com/news/home/20260501598378/it 2026-05-03T13:50:00.000Z weekly 0.5 Business Wire it PressRelease 2026-05-03T13:50:00.000Z Riassunto: Incyte annuncia l'approvazione dell'FDA di Jakafi XR™ (ruxolitinib) compresse a rilascio prolungato per il trattamento della mielofibrosi, della policitemia vera e della malattia del trapianto contro l'ospite INCY https://mms.businesswire.com/media/20260501598378/it/2792366/21/JAKAFIXR_US_TM_5dose_RGB_FC_Pos_White-002.jpg https://www.businesswire.com/news/home/20260501479408/es 2026-05-03T13:50:00.000Z weekly 0.5 Business Wire es PressRelease 2026-05-03T13:50:00.000Z Resumen: Incyte anuncia la aprobación de la FDA para Jakafi XR™ (ruxolitinib) en comprimidos de liberación prolongada para tratar la mielofibrosis, la policitemia vera y la enfermedad de injerto contra huésped INCY https://mms.businesswire.com/media/20260501479408/es/2792366/21/JAKAFIXR_US_TM_5dose_RGB_FC_Pos_White-002.jpg https://www.businesswire.com/news/home/20260501750381/fr 2026-05-03T13:50:00.000Z weekly 0.5 Business Wire fr PressRelease 2026-05-03T13:50:00.000Z Incyte annonce l’autorisation par la FDA des comprimés à libération prolongée Jakafi XR™ (ruxolitinib) pour le traitement de la myélofibrose, de la polycythémie vraie et de la maladie du greffon contre l’hôte INCY https://mms.businesswire.com/media/20260501750381/fr/2792366/21/JAKAFIXR_US_TM_5dose_RGB_FC_Pos_White-002.jpg https://www.businesswire.com/news/home/20260501406597/nl 2026-05-03T13:50:00.000Z weekly 0.5 Business Wire nl PressRelease 2026-05-03T13:50:00.000Z Samenvatting: Incyte maakt bekend dat de FDA goedkeuring heeft verleend voor Jakafi XR™ (ruxolitinib) tabletten met vertraagde afgifte voor de behandeling van myelofibrose, polycythemia vera en graft-versus-hostziekte INCY https://mms.businesswire.com/media/20260501406597/nl/2792366/21/JAKAFIXR_US_TM_5dose_RGB_FC_Pos_White-002.jpg https://www.businesswire.com/news/home/20260503216574/en/Planet-Launches-Three-Additional-High-Resolution-Pelican-Satellites 2026-05-03T10:37:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-03T10:37:00.000Z Planet Launches Three Additional High-Resolution Pelican Satellites PL https://mms.businesswire.com/media/20260503216574/en/1667152/21/logo.jpg https://www.businesswire.com/news/home/20260502981693/en/NomosLogic-Founder-Matt-Hardy-Launches-Lyceum-and-Odyssey-on-Dendrite-Lite 2026-05-03T01:27:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-03T01:27:00.000Z NomosLogic Founder Matt Hardy Launches Lyceum and Odyssey on Dendrite Lite https://mms.businesswire.com/media/20260502981693/en/2792831/21/NomosLogic_Lyceum_%26_Odyssey_Launch_1080p_caption.jpg